Artivion's AMDS Trials Showcase Innovative Aortic Disease Treatments at EACTS Annual Meeting
- Artivion showcased AMDS trial results, demonstrating significant patient recovery from severe aortic conditions at EACTS.
- The AMDS PERSEVERE trial showed 83% of patients with visceral malperfusion improved within 30 days post-implantation.
- Artivion emphasizes its commitment to innovative aortic disease treatments, enhancing patient care through advanced technology.
Artivion Showcases Groundbreaking Advances in Aortic Disease Treatment at EACTS
Artivion, Inc., a leader in the field of cardiac and vascular surgery, presents impactful findings from its recent AMDS PERSEVERE and PROTECT trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Copenhagen. These pivotal studies focus on the company's AMDS hybrid prosthesis, which addresses aortic disease, particularly in patients suffering from severe conditions such as acute DeBakey Type I dissection. The AMDS PERSEVERE trial reports that an impressive 83% of patients with visceral malperfusion and 74% with renal malperfusion see their conditions resolve within 30 days post-implantation. This robust data underscores the potential of AMDS technology to deliver significant clinical improvements for patients facing dire health challenges.
The AMDS PERSEVERE trial, which included 40 participants, highlights not only the immediate efficacy of the hybrid prosthesis but also its role in preventing severe complications. According to the trial's findings, 83% of patients with pre-operative visceral malperfusion manage to avoid severe gastrointestinal issues, while 74% of those with renal malperfusion do not require dialysis or artery stenting. This data is vital as it demonstrates the AMDS technology's capability to enhance patient outcomes and quality of life in critical situations, solidifying Artivion's position as an innovator in the treatment of complex aortic conditions.
Dr. Michael Moon, a prominent figure involved in both trials, accentuates the importance of the AMDS technology in improving outcomes for severely ill patients. Meanwhile, Artivion's Chairman, President, and CEO, Pat Mackin, expresses pride in the company’s representation at EACTS, noting that the findings validate their innovative portfolio tailored for treating aortic disease. The AMDS PROTECT trial further corroborates the positive results from the PERSEVERE study, producing real-world data that indicates statistically significant health improvements. This alignment of clinical and real-world evidence enhances the confidence in AMDS technology's effectiveness, signifying a promising advancement in the field of cardiac and vascular surgery.
In addition to these findings, Artivion's presentation at EACTS serves to strengthen its commitment to addressing aortic disease through innovative solutions. The outcomes from both trials not only reassure the medical community of the reliability of AMDS technology but also reflect the ongoing dedication to improving treatment protocols for complex aortic conditions. As the industry continues to evolve, Artivion remains at the forefront, committed to enhancing patient care and outcomes in cardiac and vascular surgery.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

